Efficacy and Safety of Oral Dehydroepiandrosterone as a Concomitant Therapy to Oral Contraceptives in Women Complaining of Reduced Libido

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions
Libido
Interventions
DRUG

Dehydroepiandrosterone, BAY86-5314

Treatment with daily oral intake of two capsules containing 50 mg DHEA each. Treatment duration will be 24 weeks

DRUG

Placebo

Treatment with daily oral intake of two capsules containing Placebo. Treatment duration will be 24 weeks

Trial Locations (11)

10115

Berlin

10247

Berlin

10627

Berlin

10629

Berlin

10709

Berlin

12435

Berlin

13086

Berlin

13353

Berlin

13357

Berlin

14195

Berlin

22143

Hamburg

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY